Attention Deficit (ADHD) Drugs Linked to Cardiovascular Risk
A recent article in the New England Journal of Medicine discusses the widely prescribed class of drugs to treat ADHD and their association with cardiovascular events. On February 9, 2006, the Drug Safety and Risk Management Advisory Committee of the FDA voted by a narrow margin to place a black box warning on all ADHD drugs for cardiovascular risks such as heart attack and stroke. In spite of the Committe recommendation, the FDA recently refused to add the warnings.
The NEJM release discussing the article may be found here.
Post A Comment / Question